TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled Study of Light Therapy for Antepartum Depression
Brief Summary: The purpose of this study is to determine whether morning bright light therapy is an effective treatment for major depression during pregnancy compared with low-intensity placebo light therapy, when administered 60 minutes daily for 5 weeks.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): 1, 2
B: Arm Label: Active acupuncture group; Type: EXPERIMENTAL; Interventions: Procedure: Active acupuncture | Arm Label: Placebo acupuncture group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo acupuncture | Intervention Type: PROCEDURE; Name: Active acupuncture; Assigned to Arm(s): Active acupuncture group | Intervention Type: PROCEDURE; Name: Placebo acupuncture; Assigned to Arm(s): Placebo acupuncture group
C: Arm Label: EPA-rich fish oil supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: EPA-rich fish oil supplement | Arm Label: DHA-rich fish oil supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: DHA-rich fish oil supplement | Arm Label: Soy Oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: EPA-rich fish oil supplement; Assigned to Arm(s): EPA-rich fish oil supplement | Intervention Type: DRUG; Name: DHA-rich fish oil supplement; Assigned to Arm(s): DHA-rich fish oil supplement | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Soy Oil placebo
D: Arm Label: Bright light therapy; Type: EXPERIMENTAL; Interventions: Other: Light therapy | Arm Label: Dim red light; Type: PLACEBO_COMPARATOR; Interventions: Other: Light therapy | Intervention Type: OTHER; Name: Light therapy; Assigned to Arm(s): Bright light therapy, Dim red light

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound
Brief Summary: The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound \[IVUS\] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.


Options:
A: Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): N/A
B: Arm Label: LZ group; Type: EXPERIMENTAL; Interventions: Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | Arm Label: L group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lipitor (Atorvastatin) monotherapy | Intervention Type: DRUG; Name: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Assigned to Arm(s): LZ group | Intervention Type: DRUG; Name: Lipitor (Atorvastatin) monotherapy; Assigned to Arm(s): L group
C: Arm Label: Atorvastatin + Evacetrapib; Type: EXPERIMENTAL; Interventions: Drug: Evacetrapib, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin + Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Evacetrapib; Assigned to Arm(s): Atorvastatin + Evacetrapib | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Atorvastatin + Ezetimibe | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Atorvastatin + Evacetrapib, Atorvastatin + Ezetimibe, Atorvastatin 40 mg, Atorvastatin 80 mg
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: EZE/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EZE/simvastatin; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)
Brief Summary: Assess tolerability, transition methods and clinical effects of transition from sildenafil (Revatio) to tadalafil (Adcirca) for treatment of pulmonary arterial hypertension.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bosentan, Other: Placebo | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Bosentan, Drug: Sildenafil Citrate | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Active
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder
Brief Summary: This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.


Options:
A: Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): N/A
B: Arm Label: TROSPIUM CHLORIDE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trospium Chloride | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trospium Chloride; Assigned to Arm(s): TROSPIUM CHLORIDE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO
C: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: tolterodine; Assigned to Arm(s): tolterodine group
D: Arm Label: YM178 group; Type: EXPERIMENTAL; Interventions: Drug: YM178 | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tolterodine ER group; Type: EXPERIMENTAL; Interventions: Drug: tolterodine ER | Intervention Type: DRUG; Name: YM178; Assigned to Arm(s): YM178 group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group | Intervention Type: DRUG; Name: tolterodine ER; Assigned to Arm(s): tolterodine ER group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Bispectral Index (BIS) Monitoring of Anaesthesia With Propofol and Remifentanyl in Pediatric Patients in Ear Nose and Throat Surgery: Are There Clinical Advantages?
Brief Summary: The objective of the study is to determine wether the use of the Bispectral Index Monitor (BIS) as a method to guide anaesthesia for children in different groups of age, undergoing ear nose and throat surgery anaesthetized with an infusion of Propofol and Remifentanil with an high dose of Remifentanil (0,5-2 mcg/kg/min), can lead to a reduction in the time needed for extubation and in the amount of anesthetics used.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol, Drug: Remifentanil | Arm Label: Bispectral Index Monitor; Type: EXPERIMENTAL; Interventions: Drug: Propofol, Drug: Remifentanil, Device: Bispectral Index Monitor | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Bispectral Index Monitor, Control | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): Bispectral Index Monitor, Control | Intervention Type: DEVICE; Name: Bispectral Index Monitor; Assigned to Arm(s): Bispectral Index Monitor
B: Arm Label: anesthesia monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Arm Label: no bispectral index monitoring; Type: EXPERIMENTAL; Interventions: Device: bispectral index monitoring | Intervention Type: DEVICE; Name: bispectral index monitoring; Assigned to Arm(s): anesthesia monitoring, no bispectral index monitoring
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
D: Arm Label: BIS Monitor guided algorithm; Type: EXPERIMENTAL; Interventions: Device: BIS Monitor guided algorithm | Arm Label: Volatile anesthetic guided algorithm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volatile anesthetic guided algorithm | Intervention Type: DEVICE; Name: BIS Monitor guided algorithm; Assigned to Arm(s): BIS Monitor guided algorithm | Intervention Type: BEHAVIORAL; Name: Volatile anesthetic guided algorithm; Assigned to Arm(s): Volatile anesthetic guided algorithm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intracoronary Injection of Epo During Reperfusion in Patients Hospitalized for First Acute Myocardial Infarct STEMI
Brief Summary: Primary endpoint: Is intracoronary injection of a single dose of darbepoetin alpha, during reperfusion in patients hospitalized for ST segment elevation myocardial infarction (STEMI), able to reduce infarct size ?

In in vivo studies, many experiments evidenced infarct size reduction, due to anti-apoptotic compounds, when given during reperfusion, after cardiac ischemia. In humans, post-conditioning offers such a protection, as the investigators have previously showed (Staat P et al. Post-conditioning the human heart. Circulation. 2005 112(14):2143-8).

Infarct size reduction could lead to a reduced rate of complications (heart failure, rhythmic complications) and finally, morbidity and even mortality. This protection depends on anti-apoptotic properties (Zhao ZQ et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiology Heart Circ Physiology 2003 Aug; 285(2):H579-88). Many drugs have been proposed to be able to mimic this phenomenon. Among them, many are efficient but toxic in vivo or difficult to manage (insulin, morphin). One of the most promising agent could then be erythropoietin (EPO) (Opie LH et al. Postconditioning for protection of the infarcting heart. Lancet. 2006; 367(9509):456-8). In order to target ischemia-reperfusion injuries, EPO impact is better and better demonstrated (e.g.: Mudalagiri NR. Erythropoietin protects the human myocardium against hypoxia and reoxygenation injury via phosphatidylinositol-3 kinase and ERK1-2 activation. Br J Pharmacol. 2007 Oct 22). The purpose of the study is to test this hypothesis in humans, on the onset of the reperfusion, after myocardial ischemia (acute myocardial infarct). EPO could contribute to protect myocardium against ischemia-reperfusion injury. This impact could rely on anti-apoptotic properties.


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2
C: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dose Escalation Safety; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Arm Label: Single Dose Efficacy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): Dose Escalation Safety, Single Dose Efficacy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Brief Summary: This study is an investigational approach that uses immune cells, called "T cells", to kill leukemia. These T cells are removed from blood, modified in a laboratory, and then put back in the body. T cells fight infections and can also kill cancer cells in some cases. However, right now T cells are unable to kill the cancer cells. For this reason we will put one gene into the T cells that allows them to recognize and kill the leukemia cells. This gene will be put in the T cells by a weakened virus. The gene will produce proteins in the T cells that help the T cells recognize the leukemia cells and possibly kill them. The doctors have found that T cells modified in this way can cure an ALL-like cancer in mice.

The main goals of this study is to determine the safety and appropriate dose of these modified T cells in patients with ALL. This will be done in a "clinical trial." The dose of modified T-cells will depend on if you have disease present in your bone marrow or not. The patient will also receive chemotherapy before the T cells. We will use normally chemotherapy that is used in patients with leukemia. The chemotherapy is given to reduce leukemia and to allow the T cells to live longer.


Options:
A: Arm Label: CD30 positive NHL subtypes; Type: EXPERIMENTAL; Interventions: Drug: CD30.CAR-T | Intervention Type: DRUG; Name: CD30.CAR-T; Assigned to Arm(s): CD30 positive NHL subtypes
B: Arm Label: Pts with B Cell Acute Lymphoblastic Leukemia; Type: EXPERIMENTAL; Interventions: Biological: gene-modified T cells targeted | Intervention Type: BIOLOGICAL; Name: gene-modified T cells targeted; Assigned to Arm(s): Pts with B Cell Acute Lymphoblastic Leukemia
C: Arm Label: C-CAR011; Type: EXPERIMENTAL; Interventions: Biological: C-CAR-011 | Intervention Type: BIOLOGICAL; Name: C-CAR-011; Assigned to Arm(s): C-CAR011
D: Arm Label: Human CD19 targeted T Cells Injection; Type: EXPERIMENTAL; Interventions: Drug: Human CD19 targeted T Cells Injection | Intervention Type: DRUG; Name: Human CD19 targeted T Cells Injection; Assigned to Arm(s): Human CD19 targeted T Cells Injection

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outlook: An Intervention to Improve Quality of Life in Serious Illness Study
Brief Summary: The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.


Options:
A: Arm Label: Outlook Intervention; Type: EXPERIMENTAL; Interventions: Other: Life Completion | Arm Label: Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Life Completion; Assigned to Arm(s): Outlook Intervention | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention Control
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diaphragmatic breathing training; Type: EXPERIMENTAL; Interventions: Other: Diaphragmatic breathing training | Intervention Type: OTHER; Name: Diaphragmatic breathing training; Assigned to Arm(s): Diaphragmatic breathing training
C: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Behavioral: ACCESS | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACCESS; Assigned to Arm(s): ACCESS
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: case management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Third Eye Retroscope Randomized Clinical Evaluation (The "TERRACE" Study)
Brief Summary: The Third Eye® Retroscope® is a device that can be inserted through the instrument channel of a standard colonoscope to provide an additional, retrograde (or backward) view that reveals areas behind folds and flexures in the colon, and might detect additional polyps that cannot be seen with the colonoscope alone.

Patients who participate as subjects in the study will undergo two complete colonoscopy procedures, a standard colonoscopy and a colonoscopy in which a Third Eye Retroscope is used along with the same colonoscope. Half of the patients will have the standard colonoscopy first followed by the Third Eye colonoscopy, and the other half will have the Third Eye procedure first.

Results from the two groups will be analyzed and compared to determine the effectiveness of the Third Eye Retroscope for detecting additional adenomas and other polyps compared with the standard colonoscope alone.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Polp removal and identification, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: colon polyp removal, Procedure: ETMI colonoscope (ETMI scope is a FDA approved device) | Intervention Type: PROCEDURE; Name: Polp removal and identification; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: colon polyp removal; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: ETMI colonoscope (ETMI scope is a FDA approved device); Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: N/A; Interventions: N/A
C: Arm Label: Group A - COLO, then TER; Type: EXPERIMENTAL; Interventions: Device: Third Eye Retroscope | Arm Label: Group B - TER, then COLO; Type: ACTIVE_COMPARATOR; Interventions: Device: Third Eye Retroscope | Intervention Type: DEVICE; Name: Third Eye Retroscope; Assigned to Arm(s): Group A - COLO, then TER, Group B - TER, then COLO
D: Arm Label: Group A (study group); Type: ACTIVE_COMPARATOR; Interventions: Device: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system | Arm Label: Group B (control group); Type: ACTIVE_COMPARATOR; Interventions: Device: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system | Intervention Type: DEVICE; Name: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system; Assigned to Arm(s): Group A (study group), Group B (control group)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation
Brief Summary: The objective of this application is to identify a pharmacologic agent which helps couples in whom the female partner ovulates regularly successfully obtain their goal of delivering a healthy child, whose use will result in low rates of multiple gestations. The central hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly reducing the numbers of multiple gestational pregnancies that result from stimulation with clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed research is that reduction of multiple pregnancy rates could significantly reduce maternal and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals and society.


Options:
A: Arm Label: Young postmenopausal women; Type: EXPERIMENTAL; Interventions: Drug: GnRH, Drug: NAL-GLU GnRH antagonist, Drug: Estrogen patch | Arm Label: Older postmenopausal women; Type: EXPERIMENTAL; Interventions: Drug: GnRH, Drug: NAL-GLU GnRH antagonist, Drug: Estrogen patch | Intervention Type: DRUG; Name: GnRH; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women | Intervention Type: DRUG; Name: NAL-GLU GnRH antagonist; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women | Intervention Type: DRUG; Name: Estrogen patch; Assigned to Arm(s): Older postmenopausal women, Young postmenopausal women
B: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)
C: Arm Label: Endometrial injury group; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial injury | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Endometrial injury; Assigned to Arm(s): Endometrial injury group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Biopsy catheter; Type: EXPERIMENTAL; Interventions: Procedure: Endometrial biopsy | Intervention Type: PROCEDURE; Name: Endometrial biopsy; Assigned to Arm(s): Biopsy catheter | Intervention Type: PROCEDURE; Name: Endometrial Biopsy; Assigned to Arm(s): Biopsy catheter

Answer: B